- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.11. | Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights | 40 | PR Newswire | - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study -
- IND cleared for Phase 2 study of TYRA-300 in pediatric... ► Artikel lesen | |
| 07.11. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
| TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 01.11. | Tyra Biosciences Direktorin Nina Kjellson verkauft Aktien im Wert von 2,28 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 28.10. | Tyra Biosciences macht Fortschritte mit Phase-2-Studie für Achondroplasie-Behandlung | 2 | Investing.com Deutsch | ||
| 28.10. | Tyra Biosciences advances with Phase 2 trial for achondroplasia treatment | 2 | Investing.com | ||
| 28.10. | Tyra Biosciences (NASDAQ:TYRA) Sees Strong Trading Volume After Analyst Upgrade | 1 | MarketBeat | ||
| 28.10. | Tyra Biosciences stock target lifted, retains buy on clinical trial data | 2 | Investing.com | ||
| 28.10. | FDA genehmigt Tyra Biosciences' Studie für Kleinwuchs-Medikament | 2 | Investing.com Deutsch | ||
| 28.10. | FDA clears Tyra Biosciences' trial for dwarfism drug | 2 | Investing.com | ||
| 28.10. | Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) | 96 | PR Newswire | - TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies -
- First child with achondroplasia expected to be dosed in Q1 2025... ► Artikel lesen | |
| 28.10. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.10. | Why Is Cancer-Focused Tyra Biosciences Stock Falling On Friday? | 3 | Benzinga.com | ||
| 25.10. | Tyra Biosciences, Inc.: Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic ... | 84 | PR Newswire | - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population -
- At = 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved... ► Artikel lesen | |
| 23.10. | Tyra Biosciences stock soars to 52-week high of $28.86 | 2 | Investing.com | ||
| 23.10. | Tyra Biosciences-Aktie erreicht 52-Wochen-Hoch von 28,86 US-Dollar | 1 | Investing.com Deutsch | ||
| 18.10. | Tyra Biosciences issues warrants in exchange for common stock | 2 | Investing.com | ||
| 18.10. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.10. | BofA Upgrades Tyra Biosciences As Investors Focus On Preclinical Data Amid High Benchmarks Set By Johnson & Johnson's Drug | 8 | Benzinga.com | ||
| 18.10. | BofA upgrades Tyra Biosciences shares rating to Buy, raises price target | 4 | Investing.com | ||
| 16.10. | Tyra Biosciences-Aktie erreicht 52-Wochen-Hoch von 25,3 US-Dollar | 3 | Investing.com Deutsch |
Seite:
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,110 | -17,16 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,364 | -0,27 % | Defence Therapeutics Inc.: Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors | Vancouver, British Columbia--(Newsfile Corp. - December 20, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 9,900 | +2,06 % | Ginkgo Bioworks eligible for $9.4M in partnership for bioelectronic devices | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen | |
| BEAM THERAPEUTICS | 29,000 | +8,01 % | Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology ... | NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels of Hemoglobin F mAb Dosing... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,730 | 0,00 % | Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% - Here's What Happened | ||
| ARCTURUS THERAPEUTICS | 15,500 | +4,45 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,891 | +5,72 % | Assertio Holdings, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| SIGA TECHNOLOGIES | 5,930 | -1,66 % | SIGA Technologies Inc.: Interim Results from STOMP Study of SIGA's Tecovirimat in Treatment of Mpox Announced | Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpoxStudy stopped enrolling patients in all study armsResults... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 16,400 | -0,61 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| VERVE THERAPEUTICS | 5,735 | +11,04 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on November 29,... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,895 | -2,85 % | Where Will Summit Therapeutics Be in 5 Years? | ||
| BIO-PATH | 1,260 | -15,44 % | Pre-market Movers: PainReform, CURRENC Group, Bio-Path Holdings, Abpro Corporation, KULR Technology | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.35 A.M. ET).In the Green PainReform Ltd. (PRFX) is up over... ► Artikel lesen |
TYRA BIOSCIENCES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,480 (-3,30 %) liegt der Kurs bei 14,060 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TYRA BIOSCIENCES INC finden Sie auf Wallstreet Online.
